D&D Pharmatech First Quarter 2025 Earnings: ₩929 loss per share (vs ₩591 loss in 1Q 2024)

Simply Wall St

D&D Pharmatech (KOSDAQ:347850) First Quarter 2025 Results

Key Financial Results

  • Revenue: ₩1.41b (down 33% from 1Q 2024).
  • Net loss: ₩9.85b (loss widened by 79% from 1Q 2024).
  • ₩929 loss per share (further deteriorated from ₩591 loss in 1Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

KOSDAQ:A347850 Earnings and Revenue History May 19th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

D&D Pharmatech shares are up 27% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for D&D Pharmatech you should know about.

Valuation is complex, but we're here to simplify it.

Discover if D&D Pharmatech might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.